A significantly higher proportion of DUPIXENT patients achieved meaningful itch
improvement at Week 24 in PRIME (primary endpoint)1-3
Proportion of patients with ≥4-point improvement in WI-NRS at Week 241-3,a
- A nominal difference was observed at Week 4 (19% with DUPIXENT vs 4% with placebo)3
Definitive conclusions cannot be made for results earlier than 24 weeks in PRIME. Data were not multiplicity controlled.
PRIME2
- A nominal difference was observed at Week 11 (33% with DUPIXENT vs 17% with placebo), with a significantly greater proportion of DUPIXENT patients achieving a meaningful response at Week 12 (37% with DUPIXENT vs 22% with placebo; P=0.022, primary endpoint). At Week 24, 58% of DUPIXENT patients achieved significant itch relief vs 20% with placebo (P<0.001, secondary endpoint)1-3
Definitive conclusions cannot be made for results at timepoints other than Week 12 and 24 in PRIME2. Data were not multiplicity controlled.
PRIME AND PRIME2
of DUPIXENT patients had ≥4-point improvement in WI-NRS at Week 2 vs 1.9% with placebo3,4
of DUPIXENT patients had ≥4-point improvement in WI-NRS at Week 24 vs 19% with placebo3,4
Definitive conclusions cannot be made for these results as the data were not multiplicity controlled and P values were nominal.
DUPIXENT showed
consistent efficacy
regardless of patients’
atopic background1,5
PRIME AND PRIME2
Itch improvement regardless of patients’ history of atopy1,5
Definitive conclusions cannot be made for these results as the data were not
multiplicity controlled and P values were nominal.
In the PRIME trials, patients were stratified by their history of atopy.
IGA PN-S, Investigator’s Global Assessment PN-Stage; Q2W, once every 2 weeks; SD, standard deviation; WI-NRS, Worst Itch numerical rating scale.
Dosage and administration
Thinking about prescribing DUPIXENT? Find the
information you need to get started.